MUNICH, GERMANY--(Marketwire - 03/14/11) - Technolas Perfect Vision GmbH (TPV), a cataract and refractive laser company at the forefront of providing advanced eye laser treatments, today announced that the U.S. Food and Drug Administration (FDA) has approved the ZYOPTIX® Advanced Nomogram. The Advanced Nomogram is the latest, state-of-the-art methodology for use in custom LASIK eye surgery procedures when treating nearsightedness and astigmatism. This confirms that "there is convincing evidence that LASIK myopia corrections are more accurate with the Advanced Nomogram than without it."
Using the Advanced Nomogram when performing custom LASIK with the TECHNOLAS 217z100 laser, significantly improves the predictability of the results, as well as reducing the possibility of requiring a second enhancement procedure. Technolas Perfect Vision is the ONLY company in the US able to offer this latest, approved technology for LASIK on their laser platform.
The Advanced Nomogram was developed in collaboration with the Center for Visual Science, at the University of Rochester Flaum Eye Institute. The research team from the University of Rochester which developed the Advanced Nomogram was led by Dr Scott M. MacRae, a leading international refractive surgeon. According to Dr MacRae, "The results achieved using the Advanced Nomogram set a new vision quality and accuracy benchmark in LASIK surgery in the US."
Visit www.ready4lasik.com to learn more about the availability of this new approach.
About Technolas Perfect Vision GmbH
Technolas Perfect Vision GmbH (TPV) is a leading ophthalmology laser company, formed through a joint venture between Bausch + Lomb, and 20/10 Perfect Vision AG. TPV has a full range of expertise in both femtosecond and excimer businesses, with current innovations focused on laser cataract surgery and the correction of presbyopia. More company information is available at www.technolaspv.com
®/™ denote trademarks of Technolas Perfect Vision GmbH.
News Media Contact:
Email: Email Contact